Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €76.40 EUR
Change Today +0.70 / 0.92%
Volume 854.0
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 5:33 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lilly Corporate Center

Indianapolis, IN 46285

United States

Phone: 317-276-2000

Fax:

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical and animal health products. The company’s animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The company’s products are sold in approximately 120 countries. Segments Human Pharmaceutical Products segment Endocrinology Products The company’s endocrinology products include Humalog, Humalog Mix 75/25, and Humalog Mix 50/50, insulin analogs for the treatment of diabetes; Humulin, human insulin of recombinant DNA origin for the treatment of diabetes; Trajenta, for the treatment of type 2 diabetes; Jentadueto, a combination tablet of linagliptin (Trajenta) and metformin hydrochloride for use in the treatment of type 2 diabetes; Jardiance, for the treatment of type 2 diabetes (approved in the United States (U.S.), Europe, and Japan in 2014); Trulicity, for the treatment of type 2 diabetes (approved in the U.S. and Europe in 2014); Glyxambi, a combination tablet of linagliptin and empagliflozin (Jardiance) for the treatment of type 2 diabetes (approved in the U.S. in January 2015); Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Humatrope, for the treatment of human growth hormone deficiency and certain pediatric growth conditions; and Axiron, a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone. Neuroscience Products The company’s neuroscience products include Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the U.S. for the management of fibromyalgia and of chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis; Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Strattera, for the treatment of attention-deficit hyperactivity disorder; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and Amyvid, a radioactive diagnostic agent for positron emission tomography imaging of beta-amyloid neuritic plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Oncology Products The company’s oncology products comprise: Alimta, for the first-line treatment, in combination with another agent, of advanced non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent, for the treatment of malignant pleural mesothelioma. Erbitux, indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers; and as a single agent or in combination with radiation therapy for the treatment of certain types of head and neck cancers. Gemzar, for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, NSCLC, and advanced or recurrent ovarian cancer; and in the European Union (EU) for the treatment of bladder cancer. Cyramza, approved in 2014 in the U.S. and the EU both as a single agent and in combination with another agent for advanced or metastatic gastric cancer; and approved in 2014 in the U.S. in combination with another agent as a second-line treatment of metastatic

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €76.40 EUR +0.70

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.36
AbbVie Inc $69.34 USD +1.26
Amgen Inc $165.54 USD +6.95
Bristol-Myers Squibb Co $64.30 USD -1.68
Medtronic PLC $75.66 USD -0.35
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 44.0x
Price/Sales 4.6x
Price/Book 6.0x
Price/Cash Flow 45.7x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.